Age and Gender Affect Survival in Metastatic Colorectal Cancer

More News from ASCO 2008 Although men and women with metastatic colon or rectal cancer have similar overall survival after their diagnosis, age has an impact.  Women in premenopausal years, 18 to 44, live longer than younger men.  However, after the age of 75, women have significant worse survival than men. Across all age groups, Hispanics…  Read More

Provigil Helps Cancer Fatigue

Update from 2008 ASCO Meeting in Chicago Provigil® (modafinil) reduced fatigue in cancer patients receiving chemotherapy according to a study reported by Gary Morrow PhD at the 2008 ASCO meeting. Patients who were severely fatigued after their first chemotherapy treatment had less fatigue after they received Provigil than those who got a placebo. They were also…  Read More

Patricia Ganz M.D. Receives American Cancer Society Award at ASCO

Update from 2008 ASCO Meeting in Chicago Patricia Ganz, MD received the American Cancer Society Award at ASCO this year.  Professor of Medicine at the University of California at Los Angeles and Director of Cancer Prevention and Research at Jonsson Comprehensive Cancer Center, Dr. Ganz has a long history of concern for cancer patients and their…  Read More

KRAS Mutations Make a Difference In Response to Erbitux

Update from 2008 ASCO Meeting in Chicago Three studies reported during the 2008 American Society of Clinical Oncology found that colorectal cancer patients whose tumors have mutated KRAS genes do not benefit from treatment with the EGFR-inhibitor Erbitux® (cetuximab). At the same time, patients with tumors that aren’t aren’t mutated (wild-type) have significantly better results when…  Read More

Calcium and Magnesium Infusions Reduce Neurotoxicity with Oxaliplatin

Update from 2008 ASCO Meeting in Chicago A study presented during the American Society of Clinical Oncology meeting showed that adding IV infusions of calcium and magnesium to oxaliplatin treatment reduced peripheral neuropathy. Eloxatin® (oxaliplatin) is part of the FOLFOX treatments for colorectal cancer.  As doses accumulate, patients begin to experience tingling and numbness in their…  Read More

ASCO Focuses on Personalized Medicine for Colorectal Cancer

Update from 2008 ASCO Meeting in Chicago Some thoughts from Kate Murphy. . . We’ve known for a long time that cancer isn’t one disease and that colorectal cancer isn’t one disease either.  Too often the only way to know if a treatment would work for a patient was to give it to them and wait. …  Read More